BRIEF-Gilead's Odefsey meets primary objective in phase 3B studies
July 21, 2016 at 16:45 PM EDT
* Odefsey (Emtricitabine, Rilpivirine, Tenofovir Alafenamide) Meets Primary 48-Week objective in two phase 3B studies
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.